Myositis autoantibodies
- PMID: 22955022
- PMCID: PMC3874450
- DOI: 10.1097/BOR.0b013e328358bd85
Myositis autoantibodies
Abstract
Purpose of review: To review recent advances in our understanding of autoantibodies associated with dermatomyositis and the autoimmune necrotizing myopathies.
Recent findings: Autoantibodies preferentially associated with dermatomyositis include those recognizing Mi-2, MDA5, TIF1γ, and NXP-2. Each of these is associated with a distinct clinical phenotype. Autoantibodies found in patients with autoimmune necrotizing myopathies recognize signal recognition particle and 3-hydroxy-3-methylglutaryl-coenzime A reductase (HMG-CoA) reductase. The latter are found in patients with statin-associated autoimmune muscle disease.
Summary: As these are helpful both diagnostically and prognostically, a rheumatologist should be familiar with autoantibodies found in patients with dermatomyositis and the autoimmune necrotizing myopathies.
Conflict of interest statement
Drs. Casciola-Rosen and Mammen have a patent for an anti-HMGCR antibody test.
References
-
- Mammen AL. Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci. 2010 Jan;1184:134–153. - PubMed
-
- Zhang Y, LeRoy G, Seelig HP, et al. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell. 1998 Oct 16;95(2):279–289. - PubMed
-
- Kashiwagi M, Morgan BA, Georgopoulos K. The chromatin remodeler Mi-2beta is required for establishment of the basal epidermis and normal differentiation of its progeny. Development. 2007 Apr;134(8):1571–1582. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials